IL295427A - A method to reduce beta amyloid monomer levels in patients with cognitive decline - Google Patents

A method to reduce beta amyloid monomer levels in patients with cognitive decline

Info

Publication number
IL295427A
IL295427A IL295427A IL29542722A IL295427A IL 295427 A IL295427 A IL 295427A IL 295427 A IL295427 A IL 295427A IL 29542722 A IL29542722 A IL 29542722A IL 295427 A IL295427 A IL 295427A
Authority
IL
Israel
Prior art keywords
subject
amyloid
months
effective amount
therapeutically effective
Prior art date
Application number
IL295427A
Other languages
English (en)
Hebrew (he)
Original Assignee
Cognition Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognition Therapeutics Inc filed Critical Cognition Therapeutics Inc
Publication of IL295427A publication Critical patent/IL295427A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL295427A 2020-02-13 2021-02-12 A method to reduce beta amyloid monomer levels in patients with cognitive decline IL295427A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062976325P 2020-02-13 2020-02-13
PCT/US2021/018023 WO2021163613A1 (en) 2020-02-13 2021-02-12 Method of decreasing amyloid beta monomer levels in patients with cognitive decline

Publications (1)

Publication Number Publication Date
IL295427A true IL295427A (en) 2022-10-01

Family

ID=77292728

Family Applications (1)

Application Number Title Priority Date Filing Date
IL295427A IL295427A (en) 2020-02-13 2021-02-12 A method to reduce beta amyloid monomer levels in patients with cognitive decline

Country Status (8)

Country Link
US (1) US20230098944A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103604A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023513220A (cg-RX-API-DMAC7.html)
KR (1) KR20220142477A (cg-RX-API-DMAC7.html)
CN (1) CN115397849A (cg-RX-API-DMAC7.html)
AU (1) AU2021218735A1 (cg-RX-API-DMAC7.html)
IL (1) IL295427A (cg-RX-API-DMAC7.html)
WO (1) WO2021163613A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015116923A1 (en) 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
CN116867488A (zh) * 2020-12-11 2023-10-10 考格尼申治疗股份有限公司 用于治疗干性老年性黄斑变性(amd)的组合物
WO2024196799A2 (en) * 2023-03-17 2024-09-26 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
CN117945980A (zh) * 2024-01-24 2024-04-30 上海健康医学院 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用
WO2026030341A1 (en) * 2024-07-29 2026-02-05 Cognition Therapeutics, Inc. Zervimesine for treating neurodegenerative disease
WO2026119142A1 (zh) * 2024-12-03 2026-06-11 浙江径科医药有限公司 一种氘代异吲哚啉化合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学(国际)有限公司 用于治疗β-淀粉状蛋白相关疾病的治疗制剂
US20060251714A1 (en) * 2005-04-12 2006-11-09 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
WO2015116923A1 (en) * 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
US20200000822A1 (en) * 2017-02-23 2020-01-02 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
US20200338045A1 (en) * 2017-11-01 2020-10-29 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
WO2020032027A1 (ja) * 2018-08-07 2020-02-13 大日本住友製薬株式会社 アルツハイマー病の判定薬および判定方法

Also Published As

Publication number Publication date
EP4103604A1 (en) 2022-12-21
WO2021163613A1 (en) 2021-08-19
EP4103604A4 (en) 2024-03-27
AU2021218735A1 (en) 2022-09-01
JP2023513220A (ja) 2023-03-30
KR20220142477A (ko) 2022-10-21
US20230098944A1 (en) 2023-03-30
JP2026041805A (ja) 2026-03-10
CN115397849A (zh) 2022-11-25

Similar Documents

Publication Publication Date Title
US20230098944A1 (en) Method of decreasing amyloid beta monomer levels in patients with cognitive decline
US20180325862A1 (en) Methods for treating alzheimer?s disease and related disorders
US12594255B2 (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
US9579315B2 (en) Methods of treating obstructive lung diseases using bitter tastants
CA3154744A1 (en) Glp-1 receptor agonists in dementia
US20170304269A1 (en) Method for treating neurodegenerative diseases
CN110248650A (zh) 用于增强突触发生和神经突发生的方法
CN114007607A (zh) 用于治疗神经变性疾病的材料和方法
Nakhjiri et al. Spinal cord injury causes prominent tau pathology associated with brain post-injury sequela
CN115052595B (zh) 用于治疗神经学疾病或病症的新型治疗方法
JP2021523126A (ja) 蓄積した病理学的Tauタンパク質を低減する方法
RU2841658C1 (ru) Способ снижения уровней мономеров бета-амилоида у пациентов со снижением когнитивных способностей
CN104780917B (zh) 基于巴氯芬和阿坎酸的黄斑变性病症的疗法
HK40083593A (en) Method of decreasing amyloid beta monomer levels in patients with cognitive decline
Temnik et al. Intravenous 64Zn-aspartate mitigates neuroinflammation and motor dysfunction in an LPS-induced Parkinson’s disease rat model
CN119055674B (zh) 一种可改善认知的组合物及其在阿尔茨海默病防治中的应用
Ueda et al. Perampanel Blocks Transsynaptic α‐Synuclein Propagation and Neurodegeneration in a Mouse Model of Lewy Body Disease
US10092612B2 (en) Garcinia mangostana composition, medication and health food including the same
Heale Alterations in autophagy marker distribution in different genetic subtypes of frontotemporal lobar degeneration
WO2025221208A1 (en) Use of mitoxantrone hydrochloride as a therapeutic drug for treating neurodegenerative disorders
EP4661859A1 (en) Oral phenylbutyrate for treatment of human 4-repeat tauopathies
JP2025510556A (ja) アルツハイマー型認知症に罹患している患者の治療において使用するためのスフィンゴシン-1-リン酸受容体(s1pr)モジュレーター
US20190307833A1 (en) Treatment of age-related macular degeneration with neurotrophic peptidergic compound
JP2026502145A (ja) プリオン病に対する治療化合物としてのウロポルフィリンi
Killinger Axonal Transport, Parkin, And Α-Synuclein; Novel Therapeutic Targets To Treat Methamphetamine Neurotoxicity